Cleared Traditional

K002587 - BRANAN MEDICAL CORPORATION MONITECT METHAMPHETAMINE 500 DRUG SCREEN TEST

K002587 is an FDA 510(k) clearance for BRANAN MEDICAL CORPORATION MONITECT MET..., manufactured by Branan Medical Corporation. The device is a Class 2 Toxicology device with product code DJC cleared through the Traditional 510(k) pathway after a 93-day FDA review.

K002587 · Branan Medical Corporation · Toxicology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Nov 2000
Decision
93d
Days
Class 2
Risk

K002587 is an FDA 510(k) clearance for the BRANAN MEDICAL CORPORATION MONITECT METHAMPHETAMINE 500 DRUG SCREEN TEST. Classified as Thin Layer Chromatography, Methamphetamine (product code DJC), Class II - Special Controls.

Submitted by Branan Medical Corporation (Irvine, US). The FDA issued a Cleared decision on November 22, 2000 after a review of 93 days - within the typical 510(k) review window.

This device falls under the Toxicology FDA review panel, regulated under 21 CFR 862.3610 - the FDA toxicology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Toxicology review framework, consistent with the majority of Class II 510(k) submissions.

View all Branan Medical Corporation devices

FDA 510(k) Submission Details - K002587

510(k) Number K002587 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received August 21, 2000
Decision Date November 22, 2000
Days to Decision 93 days
Submission Type Traditional
Review Panel Toxicology (TX)
Summary Statement
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
6d slower than avg
Panel avg: 87d · This submission: 93d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

DJC Device Classification - Class 2, Special Controls

Product Code DJC Thin Layer Chromatography, Methamphetamine
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.3610
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Toxicology devices follow this clearance model.

Regulatory Peers - DJC Thin Layer Chromatography, Methamphetamine

All 23
Devices cleared under the same product code (DJC) and FDA review panel - the closest regulatory comparables to K002587.
VERDICT-II
K022141 · Medtox Diagnostics, Inc. · Jul 2002
RAPIDONE-ECSTASY TEST
K013180 · American Bio Medica Corp. · Nov 2001
VERDICT -II METHAMPHETAMINE
K010226 · Medtox Diagnostics, Inc. · Jun 2001
INSTANT-VIEW METHAMPHETAMINE URINE DIP STRIP TEST
K994406 · Alfa Scientific Designs, Inc. · Aug 2000
INSTANT-VIEW METHAMPHETAMINE URINE CASSETTE TEST
K994400 · Alfa Scientific Designs, Inc. · Aug 2000
ONTRAK TESTCUP PRO-5, MODEL 1986678
K001356 · Roche Diagnostics Corp. · Jul 2000